Home › Funds › Davern Capital Partners, LP › AVTX
Davern Capital Partners, LP position in AVTX
AVALO THERAPEUTICS INC · Health Care
Davern Capital Partners, LP reported holding 564,441 shares of AVTX (AVALO THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$8.7M, representing 1.68% of its reported portfolio and ranking #17 among its reported holdings. Davern Capital Partners, LP has disclosed AVTX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-12 · Source: SEC EDGAR Form 13F-HR
How Davern Capital Partners, LP's AVTX position evolved
Davern Capital Partners, LP first disclosed a stake in AVTX in Q2 2026 at 468,666 shares (US$8.7M). Across 2 filings, Davern Capital Partners, LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 564,441 shares valued at US$8.7M — an increase of 95,775 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 468.67K | $8.66M | New |
| Q3 2026 | 564.44K | $8.65M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AVTX and 13F data
AVTX (AVALO THERAPEUTICS INC) is a Health Care company. 83 other funds we track also report a position in AVTX — the largest reported positions include Deep Track Capital, LP (US$66.7M), Caligan Partners LP (US$58.5M), TCG Crossover Management, LLC (US$55.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AVTX
- Deep Track Capital, LP 3.61M sh · $66.71M · Q2 2026
- Caligan Partners LP 3.16M sh · $58.47M · Q2 2026
- TCG Crossover Management, LLC 3.02M sh · $55.76M · Q2 2026
- Affinity Asset Advisors, LLC 2.90M sh · $53.59M · Q2 2026
- Farallon Capital Management 2.50M sh · $46.16M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 2.50M sh · $46.16M · Q2 2026
- Avoro Capital Advisors LLC 2.33M sh · $43.12M · Q2 2026
- BVF INC/IL 2.08M sh · $38.36M · Q2 2026
- Nantahala Capital Management, LLC 1.86M sh · $34.41M · Q2 2026
- Soleus Capital Management, L.P. 1.65M sh · $30.58M · Q2 2026
- BRAIDWELL LP 1.63M sh · $30.11M · Q2 2026
- Logos Global Management LP 1.15M sh · $21.25M · Q2 2026
More on Davern Capital Partners, LP
FAQ
How long has Davern Capital Partners, LP held AVTX?
Davern Capital Partners, LP has disclosed AVTX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Davern Capital Partners, LP's current position in AVTX?
As of Q3 2026, Davern Capital Partners, LP holds 564.44K shares of AVTX (AVALO THERAPEUTICS INC), valued at $8.65M, representing 1.68% of its reported portfolio and ranking #17.
Has Davern Capital Partners, LP been buying or selling AVTX?
In the latest 13F filing (Q3 2026), Davern Capital Partners, LP increased its position in AVTX.
Which other funds hold AVTX?
Other major institutional holders of AVTX include Deep Track Capital, LP, Caligan Partners LP, TCG Crossover Management, LLC, among 83 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.